MIST Share Price | Milestone Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: How big is Milestone Pharmaceuticals, Inc.?

Market Cap: As of Jun 18, Milestone Pharmaceuticals, Inc. has a market capitalization of 92.49 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Milestone Pharmaceuticals reported net sales of 0.00 million and a net profit of -51.92 million.Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 13.15 million, while total assets were reported at 75.50 million.

Q: What does Milestone Pharmaceuticals, Inc. do?

Overview: Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing etripamil for the treatment of cardiovascular indications within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -21 Million (Quarterly Results - Mar 2025) Market cap: USD 92.49 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: 0.18 Return on Equity: 848.05% Price to Book: -15.11Contact Details: Address: 1111 Dr.-Frederik-Philips Blvd Suite 420, SAINT-LAURENT QC: H4M 2X6 Tel: 1 514 3360444 Website: https://www.milestonepharma.com

Q: Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?

As of 13 May 2024, the valuation grade for Milestone Pharmaceuticals, Inc. has moved from risky to does not qualify, indicating a significant downgrade in its investment appeal. The company is currently considered overvalued, reflected by its negative Price to Book Value of -15.11 and EV to EBITDA of -1.76. Additionally, the ROE is negative due to a lack of positive book value, further emphasizing the company's financial struggles.In comparison to its peers, Milestone's EV to EBIT ratio of -1.74 stands out against Eton Pharmaceuticals, Inc. with a ratio of -92.8956, and Abeona Therapeutics, Inc. at -4.5154, both of which are also classified as risky. The stark negative ratios across the board suggest that the company is not generating value relative to its peers. Despite a recent uptick in stock price, Milestone's year-to-date return of -25.42% compared to the S&P 500's 2.44% reinforces the notion that it is not a favorable investment at this time.

Q: Is Milestone Pharmaceuticals, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Milestone Pharmaceuticals, Inc. has changed from mildly bullish to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. Bollinger Bands indicate a bullish stance on the monthly timeframe and mildly bullish on the weekly. However, daily moving averages are mildly bearish, and the KST shows a mixed picture with weekly mildly bearish and monthly mildly bullish signals. The Dow Theory reflects a mildly bullish weekly trend but a mildly bearish monthly trend. In terms of performance, the stock has outperformed the S&P 500 over the past week and month, with returns of 2.09% and 14.71% compared to 1.05% and 2.33% for the index, respectively. However, it has significantly underperformed over longer periods, particularly in the 3-year and 5-year comparisons. Overall, the current technical stance is bullish, supported by strong weekly indicators despite some mixed signals in other timeframes.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.92 M

Shareholding (Sep 2025)

FII

1.87%

Held by 17 FIIs

DII

90.9%

Held by 7 DIIs

Promoter

3.44%

How big is Milestone Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Milestone Pharmaceuticals, Inc. has a market capitalization of 92.49 million, with net sales of 0.00 million and a net profit of -51.92 million over the last four quarters. The company's shareholder's funds are 13.15 million, and total assets are 75.50 million.

View full answer

What does Milestone Pharmaceuticals, Inc. do?

22-Jun-2025

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing etripamil for cardiovascular treatments. As of March 2025, it has a market cap of $92.49 million and reported a net profit loss of $21 million.

View full answer

Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of May 13, 2024, Milestone Pharmaceuticals, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial metrics, including a Price to Book Value of -15.11 and a year-to-date return of -25.42%, significantly underperforming compared to the S&P 500.

View full answer

Is Milestone Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Milestone Pharmaceuticals, Inc. shows a bullish technical trend with strong weekly indicators, despite mixed signals on daily and monthly timeframes, and has outperformed the S&P 500 recently, although it has underperformed over longer periods.

View full answer

Compare Milestone Pharmaceuticals, Inc. with Similar Stocks

MediciNova, Inc.Abeona Therapeutics, Inc.ProQR Therapeutics NV

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 171 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.26

Return on Equity

-282.97%

Price to Book

8.35

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-12 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.52%

6 Months

15.44%

1 Year

-13.57%

2 Years

5.52%

3 Years

-58.15%

4 Years

-73.9%

5 Years

-78.36%

Milestone Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

2.30%

EBIT to Interest (avg)

-36.88

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

0.18

Sales to Capital Employed (avg)

0.05

Tax Ratio

0.54%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

36.81%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

-15.11

EV to EBIT

-1.74

EV to EBITDA

-1.76

EV to Capital Employed

-12.60

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

Negative BV

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 4 Schemes (3.78%)

Foreign Institutions

Held by 17 Foreign Institutions (1.87%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 8.46% vs 37.50% in Jun 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.90",
          "val2": "-12.60",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "1.00",
          "val2": "1.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-11.90",
          "val2": "-13.00",
          "chgp": "8.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -80.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 30.49% vs -2.23% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.00",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.70",
          "val2": "-60.80",
          "chgp": "31.41%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.60",
          "val2": "2.60",
          "chgp": "38.46%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-41.50",
          "val2": "-59.70",
          "chgp": "30.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-61,410.00%",
          "chgp": "6,141.00%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Sep'25

Jun'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-11.90

-12.60

5.56%

Interest

1.00

Exceptional Items

0.00

Consolidate Net Profit

-11.90

-13.00

8.46%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Jun 2025

Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 8.46% vs 37.50% in Jun 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

1.00

-100.00%

Operating Profit (PBDIT) excl Other Income

-41.70

-60.80

31.41%

Interest

3.60

2.60

38.46%

Exceptional Items

0.00

Consolidate Net Profit

-41.50

-59.70

30.49%

Operating Profit Margin (Excl OI)

0.00%

-61,410.00%

6,141.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -80.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 30.49% vs -2.23% in Dec 2023

All Annual Results

Company CV

About Milestone Pharmaceuticals, Inc.

Milestone Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It is also focused on developing treatments for other indications, such as Atrial Fibrillation and Angina. Etripamil is in Phase-III development for PSVT.

Company Coordinates

Company Details

1111 Dr.-Frederik-Philips Blvd Suite 420 , SAINT-LAURENT QC : H4M 2X6

Tel: 1 514 3360444

https://www.milestonepharma.com

Registrar Details

Milestone Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Milestone Pharmaceuticals, Inc.?

Watch in Real-Time

What does Milestone Pharmaceuticals, Inc. do?

Is Milestone Pharmaceuticals, Inc. overvalued or undervalued?

Is Milestone Pharmaceuticals, Inc. technically bullish or bearish?

Compare Milestone Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Milestone Pharmaceuticals, Inc.

Company Coordinates